Extracellular vesicle scores largely remained stable on placebo, whereas KP405 was associated with statistically significant but variable within-subject shifts in insulin signaling, neuroprotection, ...
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Phase 3 randomized-withdrawal data in pediatrics indicated relapse in 41.9% continuing ecopipam versus 68.1% on placebo, a 53% relative relapse-risk reduction (HR, 0.50; P = .008). New analyses from ...
Cluster headache care remains hindered by migraine overlap, contributing to diagnostic delay and prolonged unmet need for ...
Treatment initiation before 90 days correlated with markedly higher independent walking (73.2% vs 36.7%) and fewer ...
NeurologyLive Brain Games is a weekly quiz series that goes live every Sunday morning, featuring questions on a variety of ...
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized ...
Tasimelteon advanced sleep onset by 42.5 minutes versus 5.4 minutes with placebo in DSWPD, meeting the primary endpoint with ...
The investigators set out to indirectly compare nipocalimab's safety, specifically any adverse event (AE) and any serious ...
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results